Senologie - Zeitschrift für Mammadiagnostik und -therapie 2021; 18(02): e11
DOI: 10.1055/s-0041-1730161
Abstracts
Senologie

Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: update from the MONARCH 2 study of abemaciclib plus fulvestrant

Authors

  • EM Grischke

    1   Universitätsklinikum Tübingen Frauenklinik, Tübingen, Deutschland

  • S Tolaney

    2   Dana-Farber Cancer Institute, Boston, Vereinigte Staaten von Amerika

  • W Sledge

  • G Jr

    3   Stanford University, Stanford, Vereinigte Staaten von Amerika

  • M Toi

    4   Kyoto University, Kyoto, Japan

  • P Neven

    5   Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgien

  • J Sohn

    6   Yonsei Cancer Center, Seoul, Korea, Republik

  • H Soliman

    7   Moffitt Cancer Center, Tampa, Vereinigte Staaten von Amerika
    • M. Litchfield L,

  • H Wang

    8   Eli Lilly and Company, Indianapolis, Vereinigte Staaten von Amerika

  • S Wijayawardana

    8   Eli Lilly and Company, Indianapolis, Vereinigte Staaten von Amerika
    • M. Jansen V
Weitere Informationen
Auch verfügbar auf
 

Goal To assess overall survival (OS), time to chemotherapy (TTC) and chemotherapy-free survival (CFS) in patients with and without PIK3CA mutations in MONARCH 2.

Material and method MONARCH 2 was a global, randomized, double-blind phase III trial of abemaciclib+fulvestrant or placebo+fulvestrant in pre-/perimenopausal (with ovarian suppression) and postmenopausal women with endocrine therapy resistant HR+, HER2- advanced breast cancer. Results of PIK3CA mutation status (E542K; E545K; H1047L; H1047R) from baseline ctDNA were available for 238 patients. Exploratory analyses of OS, TTC and CFS were assessed in patients with/without PIK3CA mutations using Cox Regression Models with treatment, PIK3CA mutation status and treatment by PIK3CA interaction term as covariates.

Results Abemaciclib+fulvestrant demonstrated a similar OS benefit in PIK3CA mutant (hazard ratio [HR]: 0.57; 95 % confidence interval [CI]: 0.34, 0.96) and PIK3CA wild-type (HR: 0.56; 95 %CI: 0.34, 0.91) versus placebo+fulvestrant. TTC was longer for abemaciclib+fulvestrant versus placebo+fulvestrant both in PIK3CA mutant (HR: 0.65; 95 %CI: 0.37, 1.18) and PIK3CA wild-type (HR: 0.50; 95 %CI: 0.31, 0.78). CFS was also longer for abemaciclib+fulvestrant versus placebo+fulvestrant both in PIK3CA mutant (HR: 0.63; 95 %CI: 0.39, 1.03) and PIK3CA wild-type (HR: 0.53; 95 %CI: 0.35, 0.80).

Summary In this exploratory analysis of MONARCH 2, abemaciclib+fulvestrant demonstrated benefit in OS, TTC and CFS in patients with and without PIK3CA mutations.



Publikationsverlauf

Artikel online veröffentlicht:
01. Juni 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany